NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have been given a consensus rating of "Hold" by the eleven analysts that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $13.83.

A number of brokerages have recently weighed in on NEO. Morgan Stanley dropped their price objective on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. Piper Sandler set a $12.00 price objective on NeoGenomics and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group decreased their target price on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, April 30th.

NeoGenomics Price Performance

Shares of NASDAQ NEO traded down $0.05 during midday trading on Friday, hitting $7.37. The stock had a trading volume of 866,075 shares, compared to its average volume of 1,154,726. The company has a market capitalization of $948.48 million, a PE ratio of -11.89 and a beta of 1.60. The stock has a 50 day simple moving average of $8.59 and a 200-day simple moving average of $12.45. NeoGenomics has a 1 year low of $6.08 and a 1 year high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The company had revenue of $168.04 million for the quarter, compared to analysts' expectations of $171.38 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business's quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.02) EPS. On average, sell-side analysts expect that NeoGenomics will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other NeoGenomics news, Director Stephen M. Kanovsky bought 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $7.78 per share, for a total transaction of $31,120.00. Following the completion of the purchase, the director now directly owns 40,090 shares of the company's stock, valued at approximately $311,900.20. The trade was a 11.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jeffrey Scott Sherman bought 20,000 shares of the stock in a transaction dated Friday, May 2nd. The shares were acquired at an average price of $7.51 per share, with a total value of $150,200.00. Following the completion of the purchase, the chief financial officer now directly owns 158,494 shares of the company's stock, valued at approximately $1,190,289.94. This represents a 14.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 70,600 shares of company stock valued at $550,438. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of NeoGenomics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of NeoGenomics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock valued at $234,673,000 after acquiring an additional 195,793 shares in the last quarter. First Light Asset Management LLC grew its stake in shares of NeoGenomics by 90.8% during the first quarter. First Light Asset Management LLC now owns 6,042,822 shares of the medical research company's stock valued at $57,346,000 after acquiring an additional 2,875,237 shares in the last quarter. Greenhouse Funds LLLP grew its stake in shares of NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock valued at $77,487,000 after acquiring an additional 237,491 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of NeoGenomics by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock valued at $56,645,000 after acquiring an additional 78,211 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of NeoGenomics by 14.7% during the first quarter. American Century Companies Inc. now owns 3,319,602 shares of the medical research company's stock valued at $31,503,000 after acquiring an additional 426,341 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.